NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ARQT Stock Alerts $9.43 +1.30 (+15.99%) (As of 09:46 AM ET) Add Compare Share Share Today's Range$8.90▼$9.7350-Day Range$7.84▼$12.5352-Week Range$1.76▼$13.17Volume2.75 million shsAverage Volume4.32 million shsMarket Capitalization$1.09 billionP/E RatioN/ADividend YieldN/APrice Target$26.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arcutis Biotherapeutics alerts: Email Address Arcutis Biotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside229.4% Upside$26.78 Price TargetShort InterestBearish18.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 15 Articles This WeekInsider TradingSelling Shares$41,811 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.21) to ($1.37) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.69 out of 5 starsMedical Sector690th out of 928 stocksPharmaceutical Preparations Industry325th out of 431 stocks 3.4 Analyst's Opinion Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.77% of the outstanding shares of Arcutis Biotherapeutics have been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 5.7.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently increased by 10.33%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARQT. Previous Next 1.9 News and Social Media Coverage News SentimentArcutis Biotherapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for Arcutis Biotherapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for ARQT on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,811.00 in company stock.Percentage Held by Insiders20.70% of the stock of Arcutis Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Arcutis Biotherapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow in the coming year, from ($2.21) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -2.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 8.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About Arcutis Biotherapeutics Stock (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Read More ARQT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARQT Stock News HeadlinesMay 15 at 7:39 AM | markets.businessinsider.comA Balanced Outlook: Maintaining Hold on Arcutis Amidst Zoryve’s Mixed Performance and Potential Growth CatalystsMay 15 at 7:39 AM | finance.yahoo.comArcutis Biotherapeutics Inc (ARQT) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...May 14 at 9:38 PM | msn.comArcutis Biotherapeutics Stock Climbs After Blockbuster Q1 ResultsMay 14 at 9:04 PM | investorplace.comARQT Stock Earnings: Arcutis Biotherapeutics Beats EPS, Beats Revenue for Q1 2024May 14 at 4:37 PM | markets.businessinsider.comArcutis Biotherapeutics: Strong Prescription Growth Fuels Buy RatingMay 14 at 4:00 PM | globenewswire.comArcutis Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 13 at 8:30 PM | msn.comArcutis Biotherapeutics Q1 2024 Earnings PreviewMay 13 at 8:00 AM | globenewswire.comExpert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic DermatologyMay 12 at 4:03 AM | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 5.4%May 12 at 1:56 AM | americanbankingnews.comArcutis Biotherapeutics (ARQT) to Release Earnings on TuesdayMay 5, 2024 | americanbankingnews.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 6.7%May 4, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 3, 2024 | globenewswire.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 29, 2024 | globenewswire.comArcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024April 26, 2024 | finance.yahoo.comIndustry Analysts Just Made A Captivating Upgrade To Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue ForecastsApril 22, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)April 12, 2024 | morningstar.comArcutis Biotherapeutics Inc Ordinary Shares ARQTApril 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)April 12, 2024 | markets.businessinsider.comEvaluating Arcutis Biotherapeutics: Insights From 5 Financial AnalystsApril 10, 2024 | finanznachrichten.deArcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial OfficerApril 10, 2024 | markets.businessinsider.comArcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFOApril 10, 2024 | marketwatch.comArcutis Biotherapeutics Names David Topper as Finance ChiefApril 10, 2024 | markets.businessinsider.comBuy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside PotentialApril 10, 2024 | msn.comArcutis Biotherapeutics appoints CFOApril 10, 2024 | globenewswire.comArcutis Appoints David Topper as Chief Financial OfficerSee More Headlines Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today5/14/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARQT CUSIPN/A CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees296Year Founded2016Price Target and Rating Average Stock Price Target$26.56 High Stock Price Target$50.00 Low Stock Price Target$8.00 Potential Upside/Downside+226.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-262,140,000.00 Net Margins-439.79% Pretax Margin-434.57% Return on Equity-294.85% Return on Assets-78.57% Debt Debt-to-Equity Ratio2.28 Current Ratio7.08 Quick Ratio6.80 Sales & Book Value Annual Sales$59.61 million Price / Sales15.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book8.65Miscellaneous Outstanding Shares115,530,000Free Float91,611,000Market Cap$939.26 million OptionableOptionable Beta1.18 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Todd Franklin Watanabe M.A. (Age 56)President, CEO & Director Comp: $1.01MDr. Bhaskar Chaudhuri Ph.D. (Age 69)Co-Founder & Independent Director Comp: $59.67kMr. Masaru Matsuda Esq. (Age 53)J.D., Senior VP, General Counsel & Corporate Secretary Comp: $626.22kDr. Patrick E. Burnett M.D. (Age 52)Ph.D., Senior VP & Chief Medical Officer Comp: $689.95kMr. John W. Smither CPA (Age 71)Chief Financial Officer Comp: $410.75kMr. Rajvir MadanChief Digital & Technology OfficerMs. Latha VairavanVice President of Finance & Investor RelationsMs. Courtney Barton (Age 41)VP and Chief Compliance Officer & Privacy Officer Ms. Amanda SheldonHead of Corporate CommunicationsMs. Ayisha JeterHead of Marketing & Market AccessMore ExecutivesKey CompetitorsOcular TherapeutixNASDAQ:OCULLiquidiaNASDAQ:LQDABicycle TherapeuticsNASDAQ:BCYCCentessa PharmaceuticalsNASDAQ:CNTAOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsPEAK6 Investments LLCBought 10,000 shares on 5/15/2024Ownership: 0.026%StemPoint Capital LPBought 825,000 shares on 5/14/2024Ownership: 0.000%Ameritas Investment Partners Inc.Bought 2,800 shares on 5/13/2024Ownership: 0.007%Vanguard Group Inc.Bought 269,904 shares on 5/10/2024Ownership: 4.472%State Board of Administration of Florida Retirement SystemSold 6,760 shares on 5/9/2024Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions ARQT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcutis Biotherapeutics stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcutis Biotherapeutics in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ARQT shares. View ARQT analyst ratings or view top-rated stocks. What is Arcutis Biotherapeutics' stock price target for 2024? 8 analysts have issued twelve-month price targets for Arcutis Biotherapeutics' shares. Their ARQT share price targets range from $8.00 to $50.00. On average, they anticipate the company's share price to reach $26.78 in the next twelve months. This suggests a possible upside of 229.4% from the stock's current price. View analysts price targets for ARQT or view top-rated stocks among Wall Street analysts. How have ARQT shares performed in 2024? Arcutis Biotherapeutics' stock was trading at $3.23 at the start of the year. Since then, ARQT shares have increased by 151.7% and is now trading at $8.13. View the best growth stocks for 2024 here. When is Arcutis Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our ARQT earnings forecast. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.08. The business had revenue of $13.53 million for the quarter, compared to analyst estimates of $11.78 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 294.85% and a negative net margin of 439.79%. During the same quarter in the previous year, the business earned ($1.18) earnings per share. What ETF holds Arcutis Biotherapeutics' stock? Invesco Dorsey Wright Healthcare Momentum ETF holds 357,268 shares of ARQT stock, representing 2.32% of its portfolio. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcutis Biotherapeutics investors own include Black Diamond Therapeutics (BDTX), Pfizer (PFE), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Applied Therapeutics (APLT), Aptinyx (APTX), BioNTech (BNTX), ServiceNow (NOW), Qualys (QLYS) and AbbVie (ABBV). When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $125 million in an IPO on Friday, January 31st 2020. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities served as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Jennison Associates LLC (10.54%), Vanguard Group Inc. (4.47%), StemPoint Capital LP (0.00%), AMI Asset Management Corp (0.36%), Fishman Jay A Ltd. MI (0.23%) and Los Angeles Capital Management LLC (0.15%). Insiders that own company stock include Bhaskar Chaudhuri, David W Osborne, Howard G Welgus, Life Sciences Viii L Frazier, Masaru Matsuda, Orbimed Advisors Llc, Patricia A Turney, Patrick Burnett, Scott L Burrows and Todd Franklin Watanabe. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARQT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTrump Asset Seizure Threat Alert: Could Your Savings Be Next?American Hartford Gold GroupDoes this make you sick?Allegiance GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldBiden to Drop BOMBSHELL June 13th?Paradigm PressForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
